Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.
Healthy
Primary: Number of Treatment Related Adverse Event, Including Abnormal Laboratory Events — 1; 3; 2; 4 participants
Phase 1 N=114 A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers
Healthy Volunteers
Primary: Cmax: Maximum Observed Serum Concentration — 83000; 65200; 74400 (ng/mL)/(mg/mL)
Phase 1 N=114 A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
Healthy
Primary: AUC0-inf，Area Under the Serum Concentration Versus Time Curve，Time 0 to Infinity — 30308695.01; 28449241.04; 29050169.73 hr*ng/mL
Phase 1 N=155 Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Malignant Melanoma
Primary: Investigator-Assessed Objective Response Rate (ORR) — 12.0; 36.4; 38.5 Percentage of Participants
Phase 1 N=24 Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Malaria
Primary: Safety of MMV390048 - Number of Adverse Events — 13; 0; 9; 12 Number of adverse events
Phase 1 N=30 Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
Healthy Volunteers
Primary: Number of Treatment Emergent Adverse Events (TEAEs). — 27; 9 events
Phase 1 N=56 A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
Chronic Obstructive Pulmonary Disease
Primary: Maximum Plasma Concentration (Cmax)-Budesonide — 702.3; 452.6; 340.0; 612.0 pg/mL
Phase 1 N=20 Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Primary: Maximum Tolerated Dose (MTD) of Metformin in Combination With Concurrent Cisplatin and Radiation — NA; NA; NA mg
Phase 1 N=40 Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
ALK-activated Tumors
Primary: Incidence Rate of Dose Limiting Toxicities (DLTs) Occurring During First Cycle of Treatment — 0; 0; 0; 1 Participants
Phase 1 N=36 A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr) — 1320; 1240 picomol times hour per Liter
Phase 1 N=30 Evaluate the Safety and Efficacy of Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered With Adjuvant AS01B
Malaria
Primary: Number of Participants With Solicited Adverse Events With Each Vaccination by Grade — 0; 0; 0; 0 Participants
Phase 1 N=175 A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
Crohn's Disease · Ulcerative Colitis (Part 2 Only)
Primary: Descriptive Statistics of Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State (Part 1) — 20825679.963; 7821587.111; 12609504.125; 9377712.620…
Phase 1 N=23 Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Celiac Disease
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 2; 3; 3 Participants
Phase 1 N=23 A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants